<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 54-year-old woman with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> treated with high-dose chemotherapy and an allogenic bone marrow transplant developed <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0100704'>cortical blindness</z:hpo> while receiving tacrolimus (FK506) </plain></SENT>
<SENT sid="1" pm="."><plain>MRI showed <z:hpo ids='HP_0002500'>white matter abnormalities</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>After discontinuation of FK506, the patient's vision returned within 8 days </plain></SENT>
<SENT sid="3" pm="."><plain>FK506 neurotoxicity is similar to <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506 </plain></SENT>
</text></document>